Site-Specific Antibody-Drug Conjugates

Site-specific antibody drug conjugates are the next stage in the evolution of antibody drug conjugates. The enhanced in vivo stability, potent anti-tumor efficacy and favorable toxicology profiles make site-specific ADCs an attractive option for treating cancer patients. The well-defined structure provides a base for further optimization through structure-property-relationship. We provide a comprehensive review of site-specific ADC technologies and offer insights into the future direction of ADCs.